Skip to content
Markets News
Stocks1 min read

FDA Clears Novartis Cosentyx for Polymyalgia Rheumatica

Makkler Newsroom
November 17, 2026 · Based on reporting by GlobeNewswire

The approval gives adults with polymyalgia rheumatica who struggle with corticosteroids a new treatment option, following positive Phase III results.

Key takeaways

  • The FDA approved Cosentyx for certain adults with polymyalgia rheumatica.
  • In a Phase III trial, sustained remission at week 52 was twice as common with Cosentyx as with placebo.

The FDA approved Novartis’ Cosentyx for adults with polymyalgia rheumatica (PMR) who have not responded adequately to corticosteroids or cannot tolerate tapering them. Novartis said it is the first anti-IL-17 biologic approved in the United States for PMR.

In the Phase III REPLENISH trial, 40.5% of patients taking Cosentyx 150 mg achieved sustained remission at week 52, compared with 20.5% on placebo. Both groups followed a 24-week steroid-tapering regimen.

Serious adverse events occurred in 15.9% of the Cosentyx group and 14.2% of the placebo group. Novartis reported one fatal case of cryptococcal meningitis in a patient treated with Cosentyx.

Topics
NOVNCosentyx
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.